NASDAQ: KA - Kineta, Inc.

Altı ay boyunca karlılık: -18.63%
Sektör: Healthcare

Promosyon programı Kineta, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

daha fazla ayrıntı
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Günlük fiyat değişimi: 0% (0.4801)
Haftalık fiyat değişimi: 0% (0.4801)
Aylık fiyat değişimi: 0% (0.4801)
3 ayda fiyat değişimi: -14.27% (0.56)
Altı ayda fiyat değişimi: -18.63% (0.59)
Yıllık fiyat değişimi: -86.77% (3.63)
3 yılda fiyat değişimi: -85.09% (3.22)
5 yılda fiyat değişimi: -74.6% (1.89)
10 yılda fiyat değişimi: 0% (0.4801)
Yılbaşından bu yana fiyat değişimi: 0% (0.4801)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
Toplam: 4

Yeterlik

İsim Anlam Seviye
ROA, % -137.14 0
ROE, % -487.85 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0.5 5
Toplam: 2.35

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0838 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 8.84 2
karlılık Ebitda, % -73.68 0
karlılık EPS, % -99.21 0
Toplam: 0.4
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 yıl)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 yıl)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 yıllar)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 yıllar)
Mr. Gary Gentges Executive Vice President of Corporate Development

Adres: United States, Seattle. WA, 219 Terry Ave. N - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://kinetabio.com